| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.094 | 0.6 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | JQ12 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |